Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | KCNK3 | O14649 | 4/20 | 0.43 |
| ▸ | KCNK9 | Q9NPC2 | 4/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3071146 | 0.98 | G6PD (0.49) | G6PDCASP7CASP6RXRARXRB | |
| Hydrochloric Acid SCHEMBL3071144 | 0.97 | G6PD (0.47) | G6PDCASP7CASP6RXRARXRB | |
| SCHEMBL4870195 | 0.86 | CDK2 (0.46) | G6PDCASP7CASP6RXRARXRB | |
| SCHEMBL3534227 | 0.82 | KCNK3 (0.49) | KCNK3KCNK9KDM4EMAPK1ALDH1A1 | |
| SCHEMBL29374906 | 0.82 | KDM4E (0.53) | RXRARXRBRXRGKCNK3KCNK9 | |
| SCHEMBL219675 | 0.82 | KDM4E (0.53) | RXRARXRBRXRGKCNK3KCNK9 | |
| SCHEMBL27776209 | 0.81 | F2R (0.43) | RXRARXRBRXRGKCNK3KCNK9 | |
| SCHEMBL2061615 | 0.81 | KCNK3 (0.48) | KCNK3KCNK9ALDH1A1SCN10ARXFP1 | |
| SCHEMBL16093747 | 0.81 | RXRA (0.44) | RXRARXRBRXRGKCNK3KCNK9 | |
| SCHEMBL1970631 | 0.81 | ALB (0.52) | RXRARXRBRXRGKCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404270-B2 | Quinazoline derivatives as LPA receptor 2 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-09-02 | — | — | US | disclosed |
| EP-4072670-B1 | QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | CHIESI FARM SPA (IT) | 2023-11-22 | — | — | EP | disclosed |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| EP-4168411-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20230063121-A1 | QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-03-02 | — | — | US | disclosed |
| US-20230056253-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230056253-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| EP-4072670-A1 | QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2022-10-19 | — | — | EP | disclosed |
| US-20080058319-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-7223768-B2 | Fused ring heterocycles as potassium channel modulators | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1718639-A2 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2006-11-08 | — | — | EP | disclosed |
| US-20050282882-A1 | Diamines as modulators of chemokine receptor activity | CARTER PERCY | 2005-12-22 | — | — | US | disclosed |
| US-6974836-B2 | Diamines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| US-20050233979-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2005-10-20 | — | — | US | disclosed |
| WO-2005085236-A2 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-09-15 | — | — | WO | disclosed |
| EP-1351924-A2 | DIAMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Pharma Company (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20030060459-A1 | Diamines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-03-27 | — | — | US | disclosed |
| WO-2002050019-A2 | DIAMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB PHARMA CO. (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058319-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNK17, KCNJ2, KCNJ1 | G6PD 2067/4885CASP7 828/4885CASP6 2853/4885 |
| US-12404270-B2 | Quinazoline derivatives as LPA receptor 2 inhibitors | LPAR2, LPAR1, LPAR5 | G6PD 4151/4885CASP7 3736/4885CASP6 4643/4885 |
| US-20050282882-A1 | Diamines as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | G6PD 2686/4885CASP7 3570/4885CASP6 4010/4885 |
| US-20230056253-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | G6PD 826/4885CASP7 1338/4885CASP6 1463/4885 |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | G6PD 826/4885CASP7 1338/4885CASP6 1463/4885 |
| US-20030060459-A1 | Diamines as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | G6PD 2754/4885CASP7 3719/4885CASP6 4074/4885 |
| US-20230063121-A1 | QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS | LPAR2, LPAR1, LPAR5 | G6PD 4151/4885CASP7 3736/4885CASP6 4643/4885 |
| US-20050233979-A1 | Caspase inhibitors and uses thereof | CASP1, CASP5, CASP3 | G6PD 605/4885CASP7 7/4885CASP6 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.